CODAK: An observational study in NSCLC patients receiving durvalumab
Research type
Research Study
Full title
A retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung cancer receiving durvalumab in the United Kingdom.
IRAS ID
289216
Contact name
Kevin Franks
Contact email
Sponsor organisation
AstraZeneca
Duration of Study in the UK
1 years, 7 months, 31 days
Research summary
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung cancer receiving durvalumab following platinum based chemoradiotherapy in the United Kingdom (the CODAK study). Data from this study will provide UK-specific real-world data on patients receiving durvalumab through the Early Access Programme (EAP) or post-reimbursement. The study will recruit approximately 250 patients, treated in 10 -12 UK secondary care hospitals, who were initiated on durvalumab between 1st September 2017 and 31st December 2019.
REC name
Wales REC 6
REC reference
20/WA/0329
Date of REC Opinion
2 Dec 2020
REC opinion
Favourable Opinion